• Citer

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

par Marchand, Marie ;Van Baren, Nicolas;Weynants, Patrick;Brichard, Vincent ;Brasseur, Francis;van der Bruggen, Pierre;Boon, Thierry;Coulie, Pierre G;Humblet, Yves;Bourlond, André;Vanwijck, Romain;Dreno, Brigitte;Tessier, Marie Hélène;Rankin, Elaine;Parmiani, Giorgio;Arienti, Flavio;Lienard, Danielle ;Beauduin, Marc;Dietrich, Pierre Yves;Russo, Vincenzo;Kerger, Joseph ;Masucci, Giuseppe;Jäger, Elke;De Greve, Jacques;Atzpodien, Jens
Référence International journal of cancer, 80, 2, page (219-230)
Publication Publié, 1999-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Thirty-nine tumor-bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE-3.A1 peptide at monthly intervals. No significant toxicity was observed. Of the 25 patients who received the complete treatment, 7 displayed significant tumor regressions. All but one of these regressions involved cutaneous metastases. Three regressions were complete and 2 of these led to a disease-free state, which persisted for more than 2 years after the beginning of treatment. No evidence for a cytolytic T lymphocyte (CTL) response was found in the blood of the 4 patients who were analyzed, including 2 who displayed complete tumor regression. Our results suggest that injection of the MAGE-3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced.